Vyome Inc.
HIND | NASDAQ
$1.95
+$0.02 (+1.04%)
Sep 22, 2026, 4:00 PM ET · Market open
Company Profile
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Venkateswarlu Nelabhotla | Co-Founder, Chief Executive Officer, President & Director |
| Richard Fahrner | Chief Technology Officer |
| Robert Dickey | Chief Financial Officer |
| Charles G. Chavdarian | Senior Vice President of Product Development & Regulatory CMC |
| Jules Abraham | Investor Relations Officer |
| Shiladitya Sengupta | Co-Founder, Director and Member of Scientific & Clinical Advisory Board |
| Tamara Agajanov | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Sep 01, 2026 | 3 | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| May 29, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | 8-K | Current Report |
| Mar 31, 2026 | DEF 14A | Filing |
| Mar 20, 2026 | PRE 14A | Filing |
Vyome Inc.
| Country | United States |
| IPO Date | Oct 5, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Venkateswarlu Nelabhotla |
Contact Details
Harvard Square Cambridge,
Massachusetts 02138 United States
Stock Details
| Ticker Symbol | HIND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427570 |
| CUSIP Number | 92943X104 |
| ISIN Number | US92943X1046 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove HIND